RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+15.75%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.94B
AUM Growth
+$3.94B
(+8.1%)
Cap. Flow
+$90.3M
Cap. Flow
% of AUM
2.29%
Top 10 Holdings %
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$50.5M |
| 2 |
INZY
Inozyme Pharma
INZY
|
$23.1M |
| 3 |
Kymera Therapeutics
KYMR
|
$22.9M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$21.4M |
| 5 |
Humana
HUM
|
$21.3M |
Top Sells
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$41.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$31.6M |
| 3 |
Cigna
CI
|
$30.2M |
| 4 |
Amgen
AMGN
|
$29.7M |
| 5 |
Allogene Therapeutics
ALLO
|
$18.9M |
Sector Composition
| 1 | Healthcare | 90.05% |
| 2 | Consumer Staples | 1.43% |
| 3 | Consumer Discretionary | 0.93% |
| 4 | Industrials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
151
Cigna
CI
$80.2B
| – | – |
-161,000
| Closed | -$30.2M |
|
|
BNR
152
Burning Rock Biotech
BNR
$85.6M
| – | – |
-200,000
| Closed | -$5.4M |
|
|
153
Amgen
AMGN
$153B
| – | – |
-126,000
| Closed | -$29.7M |
|
|
154
Allogene Therapeutics
ALLO
$249M
| – | – |
-440,468
| Closed | -$18.9M |
|